Single center, open-label, phase IV clinical trial to study the application of radiomics in molecular imaging for diagnosis and follow-up of CVDIs. The study will include three populations:
* Retrospective cohort (2018-2025) * Prospective cohort (2026-2027) * Control group (prospective)
Age ≥ 18 years.
Implanted cardiovascular device (prosthetic valve, TAVI, CIED, vascular graft/endograft).
For infected cohorts: patients studied by FDG-PET with definitive diagnosis of CVDI based on multidisciplinary evaluation.
For control group: no clinical suspicion of infection at time of inclusion.
Inability to undergo FDG-PET due to contraindications (e.g., allergies, claustrophobia).
Pregnancy or breastfeeding.
Incomplete clinical data or lack of access to imaging studies.
Refusal or withdrawal of informed consent (for control and prospective cohort).